Close

Rubius Therapeutics (RUBY) Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. NVDA
4. META
5. PPG
6. HDFCB:IN
7. HDB
8. WIT
9. MSFT
10. AAPL


Go back to Rubius Therapeutics (RUBY) Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

March 15, 2021 7:39 AM EDT

RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events 

RTX-240 Promoted Trafficking of NK and T Cells into
Tumor Microenvironment

Initial Clinical Data Provide Evidence of Broad Potential of RED PLATFORM® Across Pipeline of Cancer and Autoimmune Programs

Company to Host Conference Call Today at 8:00 a.m. EDT

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:... More